# Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

> **NCT00005609** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab

## Key facts

- **NCT ID:** NCT00005609
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** — (—)
- **Last updated:** 2013-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005609, "Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00005609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*